Post by Ed Piper

Helping solve unmet patient need drives everything we do at AstraZeneca. We know that autoimmune diseases are complex, heterogeneous and progressive – but that complexity is exactly why this work matters so much.    There is growing momentum across the immunology community to go deeper into disease biology to potentially deliver better outcomes for patients.   At AstraZeneca, we’re taking a biology‑first approach – looking beyond traditional disease silos to better understand shared immune pathways and signalling networks across conditions including lupus, rheumatoid arthritis and inflammatory bowel disease.   I’m excited by the progress we’re making and the potential for biology-driven innovation to help redefine what’s possible for patients.   My colleague Attilio Bondanza, MD PhD recently shared more in his article STAT: https://bit.ly/4x4Onvt